TNFRSF10D and cancer: Therefore, we stably knocked down TRAIL-R4 in two different human cancer cell lines and analyzed the activation of apoptotic and non-apoptotic, pro-inflammatory signaling pathways in response to treatment with recombinant TRAIL.